| Literature DB >> 32117077 |
Hsiao-Han Lin1,2, Manda Yu1, Manoj Kumar Sriramoju3, Shang-Te Danny Hsu3, Chi-Te Liu2,4, Erh-Min Lai1.
Abstract
The type VI secretion system (T6SS) is an effector delivery system used by Gram-negative bacteria to kill other bacteria or eukaryotic hosts to gain fitness. The plant pathogen Agrobacterium tumefaciens utilizes its T6SS to kill other bacteria, such as Escherichia coli. We observed that the A. tumefaciens T6SS-dependent killing outcome differs when using different T6SS-lacking, K-12 E. coli strains as a recipient cell. Thus, we hypothesized that the A. tumefaciens T6SS killing outcome not only relies on the T6SS activity of the attacker cells but also depends on the recipient cells. Here, we developed a high-throughput interbacterial competition platform to test the hypothesis by screening for mutants with reduced killing outcomes caused by A. tumefaciens strain C58. Among the 3,909 strains in the E. coli Keio library screened, 16 mutants with less susceptibility to A. tumefaciens C58 T6SS-dependent killing were identified, and four of them were validated by complementation test. Among the four, the clpP encoding ClpP protease, which is universal and highly conserved in both prokaryotes and eukaryotic organelles, was selected for further characterizations. We demonstrated that ClpP is responsible for enhancing susceptibility to the T6SS killing. Because ClpP protease depends on other adapter proteins such as ClpA and ClpX for substrate recognition, further mutant studies followed by complementation tests were carried out to reveal that ClpP-associated AAA+ ATPase ClpA, but not ClpX, is involved in enhancing susceptibility to A. tumefaciens T6SS killing. Moreover, functional and biochemical studies of various ClpP amino acid substitution variants provided evidence that ClpA-ClpP interaction is critical in enhancing susceptibility to the T6SS killing. This study highlights the importance of recipient factors in determining the outcome of the T6SS killing and shows the universal ClpP protease as a novel recipient factor hijacked by the T6SS of A. tumefaciens.Entities:
Keywords: Agrobacterium tumefaciens; ClpA; ClpP; Escherichia coli; antibacterial activity; recipient cells; type VI secretion system
Year: 2020 PMID: 32117077 PMCID: PMC7012810 DOI: 10.3389/fmicb.2019.03077
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Bacterial strains and plasmids.
| Strain/plasmid | Relevant characteristics | Source/references |
| C58 (EML530) | Wild-type virulence strain containing pTiC58 and pAtC58 | Eugene Nester |
| C58:△ | ( | |
| DH10B | Host for DNA cloning | Invitrogen |
| BW25113 | Wild-type strain of the Keio Collection. | ( |
| Keio collection | Systematic single-gene knockout mutants of | ( |
| JW0427 | BW25113 | ( |
| JW0866 | BW25113 | ( |
| JW0428 | BW25113 | ( |
| EML5395 | DH10B harboring pNptII | This study |
| EML5393 | BW25113 wild-type harboring pNptII | This study |
| BL21(DE3) | Host for protein expression | ( |
| pTrc200HA | SpR, pTrc200 harboring C-terminal influenza hemagglutinin (HA) epitope, P | Laboratory collection |
| pRL662 | GmR, a non-transferable broad-host range vector derived from pBBR1MCS2 | ( |
| pET22b(+) | ApR, | Novagen |
| pRL- | GmR, pRL662 expressing BW25113 | This study |
| pRL- | GmR, pRL662 expressing BW25113 | This study |
| pRL- | GmR, pRL662 expressing BW25113 | This study |
| pRL- | GmR, pRL662 expressing DH10B | This study |
| pNptII | KmR, GmR, pRL662 expressing | This study |
| pClpP-HA | SpR, pTrc200HA expressing ClpP-HA fusion protein | This study |
| pClpA-HA | SpR, pTrc200HA expressing ClpA-HA fusion protein | This study |
| pClpPS111A-HA | SpR, pTrc200HA expressing ClpP-HA fusion protein with S111A substitution | This study |
| pClpPH136A-HA | SpR, pTrc200HA expressing ClpP-HA fusion protein with H136A substitution | This study |
| pClpPD185A-HA | SpR, pTrc200HA expressing ClpP-HA fusion protein with D185A substitution | This study |
| pClpPR26A-HA | SpR, pTrc200HA expressing ClpP-HA fusion protein with R26A substitution | This study |
| pClpPD32A-HA | SpR, pTrc200HA expressing ClpP-HA fusion protein with D32A substitution | This study |
| pClpX-ΔN-ter | Plasmid used for purifying ClpX-ΔN | Robert T. Sauer |
| pGFP-ssrA | Plasmid used for purifying GFP-ssrA | Robert T. Sauer |
| pClpP-tev-His | ApR, pET22b(+) expressing ClpP-tev-His, in which ClpP protein is fused with a TEV protease cleavage site and a His-tag in its C-terminal | Robert T. Sauer |
| pClpPS111A-tev-His | ApR, pET22b(+) expressing ClpP-tev-His with ClpP S111A substitution | This study |
| pClpPH136A-tev-His | ApR, pET22b(+) expressing ClpP-tev-His with ClpP H136A substitution | This study |
| pClpPD185A-tev-His | ApR, pET22b(+) expressing ClpP-tev-His with ClpP D185A substitution | This study |
Primer information.
| Primer | Sequence (5′–3′)a | Plasmids |
| T7 | TAATACGACTCACTATAGGG | pET22b(+) |
| T7T | GCTAGTTATTGCTCAGCGG | |
| pTRC99C-F | TTGCGCCGACATCATAAC | pTrc200HA |
| pTRC99C-R | CTGCGTTCTGATTTAATCTG | |
| rpsL-fw | AAAAA | (1) pRL- |
| rpsL-rv | AAAAA | (2) pRL-rpsLStr |
| galK-fw | AAAAA | pRL-galk |
| galK-rv | AAAAA | |
| nupG-fw | AAAAA | pRL-nupG |
| nupG-rv | AAAAA | |
| NptII-fw- | AAAAA | pNptII |
| NptII-rv- | AAAAA | |
| ClpP- | AAAAA | pClpP-HA |
| ClpP- | AAAAA | |
| ClpA- | AAAAA | pClpA-HA |
| ClpA- | AAAAA | |
| ClpP-S111A-fw | TGTATGGGCCAGGCGGCC | (1) pClpPS111A-HA |
| ClpP-S111A-rv | CAGCAAGAAAGCGCCCAT | (2) pClpPS111A-tev-His |
| ClpP-H136A-fw | AATTCGCGCGTGATGATT | (1) pClpPH136A-HA |
| ClpP-H136A-rv | GTAGCCGCCCAACGGTTG | (2) pClpPH136A-tev-His |
| ClpP-D185A-fw | GAACGTGATACCGAGCGC | (1) pClpPD185A-HA |
| ClpP-D185A-rv | AGGGGCGGAAAGGAAGCG | (2) pClpPD185A-tev-His |
| ClpP-R26A-fw | GTCATTGAACAGACCTCA | pClpPR26A-HA |
| ClpP-R26A-rv | ATCAAAAGAGCGCTCACC | |
| ClpP-D32A-fw | CGCGGTGAGCGCTCTTTT | pClpPD32A-HA |
| ClpP-D32A-rv | AAGTAGACGAGAATAGAT |
FIGURE 1Agrobacterium tumefaciens type VI secretion system (T6SS)-dependent antibacterial activity against Escherichia coli strains. (A,B) A. tumefaciens T6SS antibacterial activity against E. coli strains DH10B and BW25113. A. tumefaciens was co-cultured at a ratio of 30:1 with E. coli DH10B or BW25113, both E. coli strains harboring vector pRL662, on Agrobacterium Kill (AK) agar medium for 16 h. The bacterial mixtures were serially diluted and spotted (A) or quantified by counting cfu (B) on gentamicin-containing lysogeny broth (LB) agar plates to selectively recover E. coli. (C) E. coli DH10B was complemented by either vector only (vec) or derivative expressing rpsL, galK, nupG, or rpsL before being subjected to A. tumefaciens T6SS-dependent antibacterial activity assay as described in (B). Susceptibility index (SI) was defined as the subtraction difference of the recovery log(cfu) of that attacked by ΔtssL to that attacked by wild-type A. tumefaciens C58. Data are mean ± SD of three independent experiments calculated by t-test with P < 0.05 for statistical significance (B) or single-factor analysis of variance (ANOVA) and Tukey honestly significant difference (HSD), in which two groups with significant differences are indicated with different letters (a and b) (C).
FIGURE 2The high-throughput interbacterial competition platform. (A) Interbacterial competition assay. Cultured attacker Agrobacterium tumefaciens and recipient Escherichia coli were mixed and then spotted on the Agrobacterium Kill (AK) agar medium to allow interbacterial competition for 16 h at 25°C followed by recovery of mixed cultures, serially diluted, and then spread onto lysogeny broth (LB) plate supplemented with appropriate antibiotics to select for recipient cells. (B) High-throughput interbacterial competition screening platform. Recipient cells were grown and mixed with attacker A. tumefaciens in a 96-well plate. The bacterial mixture was dropped onto the AK agar medium competition surface using an automated pipetting system. The competition surface was made on a microplate lid. Recovery was performed using microplate replicator. The candidates are the strains that show multiple colonies grown after recovery as opposed to wild-type controls and most strains with no or few colonies. This high-throughput A. tumefaciens type VI secretion system (T6SS) killing platform enables ∼400 mutant screens per day. This figure was created with BioRender (https://biorender.com/).
Escherichia coli strains that showed reduced susceptibility to Agrobacterium tumefaciens T6SS attack.
| No. | Resource | Disrupted | Gene products affected by | Reduced | Trans |
| (JW ID) | gene | kanamycin cassette insertiona | susceptibilityb | complementationc | |
| 1 | JS0427 | ClpAXP, ClpXP, ClpAP | O | O | |
| 2 | JW0710 | citrate synthase | O | O | |
| 3 | JW1658 | FAD/NAD(P) binding domain-containing protein YdhS | O | O | |
| 4 | JW1346 | Rac prophage; zinc-binding protein | O | Δ | |
| 5 | JW0985 | Curved DNA-binding protein | O | X | |
| 6 | JW1792 | Carnitine monooxygenase | X | n.d. |
FIGURE 3Agrobacterium tumefaciens susceptibility to type VI secretion system (T6SS)-dependent antibacterial activity was reduced in Escherichia coli clpP:kan and can be fully complemented in trans. (A) Recovery of surviving E. coli cells at 0 h and 16 h after being co-cultured with either A. tumefaciens wild type C58 (wt) or ΔtssL at a ratio of 30:1. (B) The susceptibility index (SI) of E. coli BW25113 wild type (BW), ΔclpP, and ΔclpP complemented with clpP expressed on plasmid (clpP+) was calculated from the recovery rate shown in (A). Statistical analysis involved single-factor analysis of variance (ANOVA) and Tukey honestly significant difference (HSD). Data are mean ± SD of three independent experiments, and two groups with significant differences are indicated with different letters (a and b) (P < 0.05 for statistical significance).
FIGURE 4Effects of ClpP protease catalytic variants in enhancing Agrobacterium tumefaciens type VI secretion system (T6SS) antibacterial activity. (A) The susceptibility index calculated from A. tumefaciens interbacterial activity assay against Escherichia coli. The A. tumefaciens C58 wild-type or ΔtssL were co-cultured at a ratio of 10:1 with E. coli BW25113 wild type (BW), ΔclpP, and ΔclpP complemented with clpP and its variants expressed on plasmid. The complemented clpP strains were either wild type (clpP+) or catalytic variants ClpPS111A (S111A+), ClpPH136A (H136A+), and ClpPD185A (D185A+), with C-terminus HA-tag. The susceptibility index (SI) of each E. coli was calculated from the logarithm recovery rate of the ΔtssL co-cultured group minus that of the wild-type co-cultured group. Data are mean ± SD of four biological replicates from two independent experiments. Statistical analysis involved single-factor analysis of variance (ANOVA) and Tukey honestly significant difference (HSD) with P < 0.05 for statistical significance. Two groups with significant differences are indicated with different letters (a and b). (B) The ClpP protein levels of the ΔclpP complemented strains used in (A). The ClpP-expressing E. coli strains were cultured at the same condition used in interbacterial competition assay. Instead of co-culture with A. tumefaciens, protein samples were collected, normalized, and subjected to Western blot analysis of ClpP:HA and its variants. Representative result of three independent experiments is shown.
FIGURE 5Protease activity assay of the ClpP and its catalytic variants. The wild-type ClpP and its catalytic variants were each pre-assembled with ClpX followed by providing its substrate, the ssrA-tagged green fluorescent protein (GFP). The GFP fluorescent signals were monitored (A) over time, and (B) statistical analysis was measured at the end of the assay. Statistical analysis involved single-factor analysis of variance (ANOVA) and Tukey honestly significant difference (HSD) with P < 0.05 for statistical significance. Two groups with significant differences are indicated with different letters (a and b). Data are mean ± SD of three biological replicates from one representative result of at least two independent experiments.
FIGURE 6ClpP associated AAA+ ATPase ClpA but not ClpX is involved in enhancing Agrobacterium tumefaciens type VI secretion system (T6SS) antibacterial activity. (A) A. tumefaciens T6SS antibacterial activity against Escherichia coliΔclpP and its complement strain, ΔclpA and ΔclpX. The A. tumefaciens and the E. coli were co-cultured at a ratio of 10:1 on Agrobacterium Kill (AK) agar medium for 16 h. Afterward, the recovery of E. coli strains was quantified, and the susceptibility index was calculated by subtracting the difference of the recovered log(cfu) of that attacked by ΔtssL to that by wild-type A. tumefaciens C58. (B) A. tumefaciens T6SS antibacterial activity assay and the susceptibility index were performed as described in (A) using E. coli wild type (BW), ΔclpA, and ΔclpA complemented with clpA expressed on plasmid (clpA+). (C) Growth of E. coli when co-culturing with the ΔtssL A. tumefaciens. Data in (A–C) are mean ± SD of at least three independent experiments. Statistical analysis involved single-factor analysis of variance (ANOVA) and Tukey honestly significant difference (HSD) with P < 0.05 for statistical significance. Two groups with significant differences are indicated with different letters (a and b).
FIGURE 7Effects of ClpP variants impaired with ClpA-binding ability in enhancing Agrobacterium tumefaciens type VI secretion system (T6SS) antibacterial activity. Interbacterial competition assay between A. tumefaciens and Escherichia coli wild type, ΔclpP, and ΔclpP complement strains expressing wild-type ClpP (clpP+), ClpAP complex formation mutants ClpPR26A (R26A+), and ClpPD32A (D32A+). The ClpAP complex forming ability is half than that of wild-type ClpP in ClpPR26A and is completely lost in ClpPD32A (Bewley et al., 2006). The T6SS killing data are mean ± SD of four biological replicates from two independent experiments. Statistical analysis involved single-factor analysis of variance (ANOVA) and Tukey honestly significant difference (HSD) with P < 0.05 for statistical significance. Two groups with significant differences are indicated with different letters (a and b).